A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
- 30 September 2005
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 150 (3), 401.e1-401.e7
- https://doi.org/10.1016/j.ahj.2005.03.017
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialAmerican Heart Journal, 2004
- Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic EventsStroke, 2004
- Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary SyndromesCirculation, 2003
- Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular DiseaseCirculation, 2003
- Scientific and therapeutic advances in antiplatelet therapyNature Reviews Drug Discovery, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsHeart, 2001
- Peripheral arterial disease - epidemiological aspectsVascular Medicine, 2001
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionThe New England Journal of Medicine, 1998
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996